{"filing":{"accession_number":"0001477932-26-005359","cik":"0000093314","ticker":"VNRX","company_name":"VOLITIONRX LTD","form":"8-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"vnrx_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793226005359/vnrx_8k.htm"},"events":[{"id":31358,"run_id":28767,"accession_number":"0001477932-26-005359","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The filing discloses a waiver and consent agreement between VolitionRx and Lind Global Asset Management that permits the Company to conduct unlimited ATM (at-the-market) offerings without triggering prohibited transaction covenants or events of default under existing convertible debt and warrant agreements. The waiver explicitly removes restrictions on ATM sales that previously capped permitted sales at $10 million per calendar year, allowing dilutive equity issuances in excess of that threshold. This is material because it materially expands the Company's ability to raise capital through dilutive equity offerings and removes contractual constraints that previously limited such issuances.","company_name":"VOLITIONRX LTD","ticker":"VNRX","filing_date":"2026-09-02","form":"8-K","submitted_at":null,"items":[{"id":34210,"accession_number":"0001477932-26-005359","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a waiver and consent agreement between VolitionRx and Lind Global Asset Management that permits the Company to conduct unlimited ATM (at-the-market) offerings without triggering prohibited transaction covenants or events of default under existing convertible debt and warrant agreements. The waiver explicitly removes restrictions on ATM sales that previously capped permitted sales at $10 million per calendar year, allowing dilutive equity issuances in excess of that threshold. This is material because it materially expands the Company's ability to raise capital through dilutive equity offerings and removes contractual constraints that previously limited such issuances.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:47:37.040577+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34210,"accession_number":"0001477932-26-005359","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a waiver and consent agreement between VolitionRx and Lind Global Asset Management that permits the Company to conduct unlimited ATM (at-the-market) offerings without triggering prohibited transaction covenants or events of default under existing convertible debt and warrant agreements. The waiver explicitly removes restrictions on ATM sales that previously capped permitted sales at $10 million per calendar year, allowing dilutive equity issuances in excess of that threshold. This is material because it materially expands the Company's ability to raise capital through dilutive equity offerings and removes contractual constraints that previously limited such issuances.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-02T20:47:37.040577+00:00","company_name":"VOLITIONRX LTD","ticker":"VNRX","filing_date":"2026-09-02"}]}